The importance of microbiological surveillance networks in monitoring resistant bacteria. RedMIVA;La importancia de las redes microbiológicas en el control de las resistencias bacterianas. RedMIVA

Revista Espanola de Quimioterapia

Volumn 20, Issue 2, 2007, Pages 193-202

  Munoz I ^a   Vanaclocha, H ^a   Gonzalez F ^a  

^a Direccion General de Salud Publica   (Spain)

Author keywords

Accumulates susceptibility test; Microbiological networks; RedMIVA; Resistance; Resistence patters

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NITROFURANTOIN; NORFLOXACIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ESCHERICHIA COLI; MICROBIAL ACTIVITY; MICROBIAL IDENTIFICATION; SENSITIVITY ANALYSIS;

BACTERIAL INFECTIONS; CANADA; DATA COLLECTION; DRUG RESISTANCE, MICROBIAL; EUROPE; HUMANS; INFORMATION DISSEMINATION; INTERNET; LABORATORIES, HOSPITAL; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PUBLIC HEALTH ADMINISTRATION; SPAIN; UNITED STATES;

EID: 34548203923     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Schuchat, A., Hilger, T., Zell, E. y cols. Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001; 7: 92-99.
2. Felmingham, D., White, A.R., Jacobs, M.R. y cols. The Alexander Project: The benefits from a decade of surveillance. J Antimicrob Chemother 2005; 56 (Suppl. 2): ii3-ii21.
3. Soriano, F., Granizo, J.J., Fenoll, A. y cols. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: Results from the cefditoren surveillance program. J Chemother 2003; 15: 107-112.
4. Jae-Hoon Song, J.H., Sook-In Jung, S.I., Ki, H.K. y cols. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: A study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004; 38: 1570-1578.
5. Carlos, C.C. The 1995 antimicrobial resistance surveillance data. Phil J Microbiol Infect Dis 1997; 26: 45-47.
6. Reynolds, R., Shackcloth, J., Felmingham, D. y cols. Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: The BSAC Respiratory Resistance Surveillance Programme. J Antimicrob Chemother 2003; 52, 931-943.
7. Sprenger, M.J., Vatopoulus, A.C., Wale, M.C., Olsson-Liljequist, B., Goettsch, W, Bronzwaer, S.L. European Antimicrobial Resistance Surveillance System (EARRS): Objectives and organization. Euro Surveill 1999; 4: 41-44.
8. Blahna, M.T., Zalewski, C.A., Reuer, J., Kahlmeter, G., Foxman, B., Marrs, C.F. The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada. J Antimicrob Chemother 2006; 57: 666-672.
9. Grupo de Trabajo EPINE. Prevalencia de las infecciones nosocomials en los hospitales españoles. Estudio del año 1990. Sociedad Española de Higiene y Medicina Preventiva Hospitalarias, Madrid 1991.
10. Gould, I.M., Krcmery, V., Helmerking, M.A European surveillance of antibiotic resistance (ESAR), a European Commission funded project. Antiinfect Drugs Chemother 2000; 17: 1-4.
11. Nissinen, A., Huovinen, P. FiRe works - The Finnish Study Group for Antimicrobial Resistance (FiRe). Euro Surveill 2000; 5: 133-135.
12. Hernández, J.R., Martínez-Martínez, L., Cantón, R., Coque, T.M., Pascual, A. and Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain. Antimicrob Agents Chemother 2005; 49: 2122-2125.
13. Archibald, L., Phillips, L., Monnet, D., McGowan, J.E., Tenover, F., Gaynes, R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-215.
14. Fridkin, S.K., Steward, C.D., Edwards, J.R. y cols. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE. phase 2. Clin Infect Dis 1999; 29: 245-252.
15. Richet, H.M., Mohammed, J., McDonald, L.C., Jarvis, W.R. Building communication network for the study and prevention for emerging antimicrobial resistance. Emerg Infect Dis 2001; 7: 319-322.
16. Turner, P.J., Greenhalgh, J.M., Edwards, J.R., McKellar, J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Programme. Int J Antimicrob Agents 1999; 13: 117-125.
17. Kresken, M., Haffner, D. Drug resistance among clinical isolates of frequently encountered clinical isolates during 1975 and 1995. Study group bacterial resistance of the Paul Ehrlich-Society for Chemotherapy. Infection 1999; 27 (Suppl. 2): 2-8.
18. Felmingham, D. Evolving resistance patterns in community-adquired respiratory tract pathogens: First results from the PROTEK global surveillance study. J Infect 2002; 44 (Suppl. A): 3-10.
19. García de Lomas, J., García-Rey, C., López, L., Gimeno, C. Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: The SAUCE project. J Antimicrob Chemother 2002; 50 (Suppl. S2): 21-26.
20. Global aspects of antimicrobial resistance among key bacterial pathogens: Results from the 1997-1999 SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 2001; 32 (Suppl. 2): S81-S167.
21. Paterson, D., Rossi, F., Baquero, F. y cols. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-973.
22. Thornsberry, C., Jones, M.E., Hickey, M.L., Mauriz, Y., Kahn, J., Sahm, D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates in the United States, 1997-1998. J. Antimicrob Chemother 1999; 44: 749-759.
23. García Rodríguez, J.A., Gomis Gavilán, M., González Núñez, J. y cols. Grupo para el Estudio del Uso Racional de los Antibióticos Orales. Informe acerca del uso racional de los antimicrobianos. Documento de consensu. Proyecto URANO. Doyma, Madrid 1999.
24. Picazo, J.J., Betriu, C., Rodríguez-Avial, I., Azahares, E., Sánchez, A.B. y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA. Enferm Infecc Microbiol Clin 2002; 20: 503-510.
25. Stelling, J.M., O'Brian, T.F. Surveillance of antimicrobial resistance: The WHONET program. Clin Infect Dis 1997; 24 (Suppl. 1): 157-188.
26. Chin, A.E., Hedberg, K., Cieslak, P.R., Cassidy, M., Stefonek, K.R., Fleming, D.W. Tracking drug-resistant Streptococcus pneumoniae in Oregon: An alternative surveillance method. Emerg Infect Dis 1999; 5: 688-693.
27. Farner, S.M. Use of local community hospital data for surveillance of antimicrobial resistance. Infect Control Hosp Epidemiol 2006; 27: 299-301.
28. Van Beneden, C.A., Lexau, C., Baughman, W. y cols. Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis 2003; 9: 1089-1095.
29. Stein, C.R., Weber, D.J., Kelley, M. Using hospital antibiogram data to assess regional pneumococcal resistance to antibiotics. Emerg Infect Dis 2003; 9: 211-216.
30. Fridkin, S.K., Edwards, J.R., Tenover, F.C., Gaynes, R.P., McGowan, J.E. Jr; Intensive Care Antimicrobial Resistance Epidemiology (ICA-RE) Project; National Nosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens assodated with hospital-acquired infections. Clin Infect Dis 2001; 33: 324-330.
31. nd ed. Approved guideline M39-A2. Wayne, PA: CLSI, 2006.
32. Hindler, J.F., Stelling, J. Analysis and presentation of cumulative antibiograms: A new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 2007; 44: 867-873.
33. Dagan, R., Klugman, K.P., Craig, W.A., Baquero, F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
34. Billstein, S.A. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob Agents Chemother 1994; 38: 2679-2682.